Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF InhibitionHélène Salmon, Miriam Mérad, Romain Remark et al.|Immunity|2016Cited by 1.2k
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy BiomarkersLisa H. Butterfield, Mary L. Disis, A. Karolina Palucka et al.|Clinical Cancer Research|2011Cited by 109